Feasibility Engine: Our Secret to Evaluating Enzymatic Routes Before Entering the Lab [Whitepaper]

Stop wasting months on routes destined to fail.
Start applying computational feasibility.

For generics companies facing patent cliff 2.0, a computational feasibility assessment can mark the difference between capturing market share and burning through R&D budgets with nothing to show for it.

Before dedicating your focus toward discovering the right enzyme for your needs, a more critical question should come first: "Where does it actually make sense to apply biocatalysis?"

Discover how computational feasibility accelerates route development and transforms biocatalysis from experimentation to strategy.

Inside this whitepaper, you'll learn:

✓ Why most biocatalysis programs fail (and how to avoid the same expensive mistakes)

✓ The three-stage framework companies get wrong—and why skipping feasibility costs you months and capital

✓ How Zymvol's Physics-AI Feasibility Engine works to screen all synthetic routes digitally before you enter the lab

✓ Real examples showing how to evaluate 14 reaction steps across 3 routes and identify the 1-2 steps where enzymes truly add value

✓ How feasibility assessment protects R&D credibility by setting realistic expectations with management before you invest

✓ Quantified advantages: Accelerate timelines from 8-18 months to 6 months while testing only 20 enzymes instead of 5,000-8,000

✓ Strategic insights for generics companies evaluating the same drugs as your competitors